CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Common Stock	Additional Paid-in Capital	Accumulated Deficit	Accumulated Other Comprehensive Loss	Total
Beginning balance at Dec. 31, 2021	$ 5	$ 785,049	$ (388,166)	$ (650)	$ 396,238
Beginning Balance (in shares) at Dec. 31, 2021	55,005,523
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of stock to collaboration partner	$ 1	26,812			26,813
Issuance of stock to collaboration partner (in shares)	2,160,760
Issuance of common stock upon the exercise of stock options		65			65
Issuance of common stock upon the exercise of stock options (in shares)	85,396
Vesting of restricted stock (in shares)	161,159
Vesting of early exercise stock options		673			673
Vesting of early exercise stock options (in shares)	173,192
Unrealized gain on short-term investments				(1,986)	(1,986)
Foreign currency translation				(6)	(6)
Stock based compensation		2,380			2,380
Net loss			(37,513)		(37,513)
Ending balance at Mar. 31, 2022	$ 6	814,979	(425,679)	(2,642)	386,664
Ending Balance (in shares) at Mar. 31, 2022	57,586,030
Beginning balance at Dec. 31, 2022	$ 6	824,292	(519,098)	(2,462)	302,738
Beginning Balance (in shares) at Dec. 31, 2022	58,473,660
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Issuance of common stock upon the exercise of stock options		448			448
Issuance of common stock upon the exercise of stock options (in shares)	452,102
Vesting of restricted stock (in shares)	95,877
Vesting of early exercise stock options		269			269
Vesting of early exercise stock options (in shares)	85,145
Unrealized gain on short-term investments				1,196	1,196
Foreign currency translation				(9)	(9)
Stock based compensation		3,797			3,797
Net loss			(31,264)		(31,264)
Ending balance at Mar. 31, 2023	$ 6	$ 828,806	$ (550,362)	$ (1,275)	$ 277,175
Ending Balance (in shares) at Mar. 31, 2023	59,106,784